Drugs / ACT100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07408908 | Mar 2026 → Mar 2027 expected | cutaneous lupus erythematosus, systemic lupus erythematosus | Xiamen Amoytop Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACT100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07408908 ↗ |
| Route | Subcutaneous | “a single 5-mg subcutaneous injection” NCT07408908 ↗ |